STAT+: A year after distressed buyout, what’s become of Bluebird Bio?

David Meek acquired Bluebird Bio (now rebranded as Genetix) when it was near bankruptcy and claims to have transformed it in a year. He predicts the company will treat 1,000 patients annually for sickle cell disease gene therapies by 2030.